| 1 | Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8 |
| 2 | Pembrolizumab leading to complete resolution of non-small cell lung cancer and microsatellite instability stable colon adenocarcinoma; two birds one stone. 2022;8:20 doi: 10.5348/100111Z10PB2022CR |
| 3 | Space-velocity thermostatted kinetic theory model of tumor growth. 2021;18:5525 doi: 10.3934/mbe.2021279 |
| 4 | Emerging Antibodies in Cancer Therapy. 2023;3:2200083 doi: 10.1002/anbr.202200083 |
| 5 | Cell density quantification with TurboSPI: R2* mapping with compensation for off-resonance fat modulation. 2020;33:469 doi: 10.1007/s10334-019-00817-4 |
| 6 | Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin. 2022;8: doi: 10.3389/fcvm.2021.812702 |
| 7 | Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. 2021;19: doi: 10.1186/s12951-021-00861-0 |
| 8 | Recent Progress of Alkyl Radicals Generation‐Based Agents for Biomedical Applications. 2021;10:2100055 doi: 10.1002/adhm.202100055 |
| 9 | Cancer Biology and Advances in Treatment. 2020;1292:113 doi: 10.1007/5584_2020_522 |
| 10 | Handbook of Cancer and Immunology. 2023;1 doi: 10.1007/978-3-030-80962-1_180-1 |
| 11 | Immunotherapy approaches for hematological cancers. 2022;25:105326 doi: 10.1016/j.isci.2022.105326 |
| 12 | Injectable immunogel based on polymerized phenylboronic acid and mannan for cancer immunotherapy. 2022;345:138 doi: 10.1016/j.jconrel.2022.03.009 |
| 13 | Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. 2021;173:281 doi: 10.1016/j.addr.2021.03.015 |
| 14 | Cancer immunotherapy: Recent advances and challenges. 2021;17:834 doi: 10.4103/jcrt.JCRT_1241_20 |
| 15 | Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients. 2022;9:327 doi: 10.3390/vetsci9070327 |
| 16 | Systems Medicine. 2021;593 doi: 10.1016/B978-0-12-801238-3.11605-8 |
| 17 | Cell Interaction - Molecular and Immunological Basis for Disease Management. 2021; doi: 10.5772/intechopen.94560 |
| 18 | A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures. 2022;103:108433 doi: 10.1016/j.intimp.2021.108433 |
| 19 | Handbook of Microbial Nanotechnology. 2022;17 doi: 10.1016/B978-0-12-823426-6.00004-8 |
| 20 | Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. 2022;10:1842 doi: 10.3390/biomedicines10081842 |
| 21 | Immunotherapies and Combination Strategies for Immuno-Oncology. 2020;21:5009 doi: 10.3390/ijms21145009 |
| 22 | Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. 2021;13:133 doi: 10.1080/19466315.2020.1814403 |
| 23 | Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50:1 doi: 10.1038/s12276-018-0115-0 |
| 24 | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. 2020;9:2967 doi: 10.3390/jcm9092967 |
| 25 | Understanding Cancer. 2022;269 doi: 10.1016/B978-0-323-99883-3.00004-4 |
| 26 | Principles of Tumors. 2020;453 doi: 10.1016/B978-0-12-816920-9.00018-3 |
| 27 | CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105 |
| 28 | Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877 |
| 29 | MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019 |
| 30 | Systemic anticancer therapies and the role of primary care. 2020;31:22 doi: 10.1002/psb.1871 |
| 31 | Peptide-based targeting of immunosuppressive cells in cancer. 2020;5:92 doi: 10.1016/j.bioactmat.2020.01.006 |
| 32 | Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. 2020;106:104722 doi: 10.1016/j.oraloncology.2020.104722 |
| 33 | The Golden Guide to Oncologic Pharmacy. 2022;243 doi: 10.1007/978-3-030-98596-7_7 |
| 34 | Studying the Anticancer Effects of Thymoquinone on Breast Cancer Cells through Natural Killer Cell Activity. 2022;2022:1 doi: 10.1155/2022/9218640 |
| 35 | Immunotherapy – A Novel Facet of Modern Therapeutics. 2021;1 doi: 10.1007/978-981-15-9038-2_1 |
| 36 | ATP stabilised and sensitised calcium phosphate nanoparticles as effective adjuvants for a DNA vaccine against cancer. 2021;9:7435 doi: 10.1039/D1TB01408K |
| 37 | Principles of Translational Science in Medicine. 2021;307 doi: 10.1016/B978-0-12-820493-1.00033-7 |
| 38 | Biomaterials for Cancer Therapeutics. 2020;331 doi: 10.1016/B978-0-08-102983-1.00012-0 |
| 39 | The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. 2022;34:189 doi: 10.3233/CBM-210349 |
| 40 | Immunostimulatory biomaterials to boost tumor immunogenicity. 2020;8:5516 doi: 10.1039/D0BM01183E |
| 41 | Tumor Innervation: History, Methodologies, and Significance. 2022;14:1979 doi: 10.3390/cancers14081979 |
| 42 | Drug Delivery Devices and Therapeutic Systems. 2021;423 doi: 10.1016/B978-0-12-819838-4.00016-X |
| 43 | Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. 2022;31:2357 doi: 10.1007/s11136-022-03110-5 |
| 44 | Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates. 2022;13: doi: 10.3389/fimmu.2022.852147 |
| 45 | Biomedical Translational Research. 2022;413 doi: 10.1007/978-981-16-8845-4_21 |
| 46 | Delivery of a Cancer-Testis Antigen-Derived Peptide Using Conformationally Restricted Dipeptide-Based Self-Assembled Nanotubes. 2021;18:3832 doi: 10.1021/acs.molpharmaceut.1c00451 |
| 47 | Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab. 2020;7: doi: 10.2217/mmt-2019-0020 |
| 48 | The discovery of potent small molecule activators of human STING. 2021;209:112869 doi: 10.1016/j.ejmech.2020.112869 |
| 49 | Nanotherapeutics in Cancer Vaccination and Challenges. 2022;29 doi: 10.1016/B978-0-12-823686-4.00018-5 |
| 50 | Cancer and the Immune System: The History and Background of Immunotherapy. 2019;35:150923 doi: 10.1016/j.soncn.2019.08.002 |
| 51 | Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. 2022;346:43 doi: 10.1016/j.jconrel.2022.04.007 |
| 52 | The need for rapid therapeutic efficacy testing for cancer therapy. 2020;113:104382 doi: 10.1016/j.yexmp.2020.104382 |
| 53 | Integrative Nanomedicine for New Therapies. 2020;321 doi: 10.1007/978-3-030-36260-7_12 |
| 54 | Emerging therapeutic agents for advanced non-small cell lung cancer. 2020;13: doi: 10.1186/s13045-020-00881-7 |
| 55 | The second near-infrared window quantum dot-based fluorescence anisotropy probes for separation-free, sensitive and rapid detection of small extracellular vesicle PD-L1 in plasma samples. 2023;376:132962 doi: 10.1016/j.snb.2022.132962 |
| 56 | Immunosuppression. 2020; doi: 10.5772/intechopen.94754 |
| 57 | Molecular and Cell Biology of Cancer. 2019;117 doi: 10.1007/978-3-030-11812-9_7 |
| 58 | Cancer Immunotherapy: Diverse Approaches and Obstacles. 2022;28:2387 doi: 10.2174/1381612828666220728160519 |
| 59 | Nano-ablative immunotherapy for cancer treatment. 2021;10:3247 doi: 10.1515/nanoph-2021-0171 |
| 60 | Targeting cancer-associated glycans as a therapeutic strategy in leukemia. 2022;15:378 doi: 10.1080/26895293.2022.2049901 |
| 61 | The pint- sized powerhouse: Illuminating the mighty role of the gut microbiome in improving the outcome of anti- cancer therapy. 2021;70:98 doi: 10.1016/j.semcancer.2020.07.012 |
| 62 | A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer. 2022;13: doi: 10.3389/fimmu.2022.845217 |
| 63 | Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment. 2022;22 doi: 10.37349/emed.2022.00072 |
| 64 | Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy. 2022;14:2606 doi: 10.3390/pharmaceutics14122606 |
| 65 | Current Applications for Overcoming Resistance to Targeted Therapies. 2019;20:97 doi: 10.1007/978-3-030-21477-7_4 |
| 66 | Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo. 2020;11:2873 doi: 10.18632/oncotarget.27556 |
| 67 | Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach. 2023;21: doi: 10.1186/s12951-022-01764-4 |
| 68 | Human health and snails. 2021;42:211 doi: 10.1080/15321819.2020.1844751 |
| 69 | William B. Coley. 2020;47:413 doi: 10.1016/j.ucl.2020.07.001 |
| 70 | The Microbiome in Health and Disease. 2020;171:301 doi: 10.1016/bs.pmbts.2020.04.004 |
| 71 | Analysis of tumor-immune functional responses in a mathematical model of neoantigen cancer vaccines. 2023;356:108966 doi: 10.1016/j.mbs.2023.108966 |
| 72 | Handbook on Synthesis Strategies for Advanced Materials. 2021;643 doi: 10.1007/978-981-16-1892-5_14 |
| 73 | CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies. 2020;19:191 doi: 10.1093/bfgp/elz039 |
| 74 | Picolylamine-functionalized benz[e]indole squaraine dyes: Synthetic approach, characterization and in vitro efficacy as potential anticancer phototherapeutic agents. 2022;229:114071 doi: 10.1016/j.ejmech.2021.114071 |
| 75 | Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy. 2022;52:415 doi: 10.1007/s40005-022-00569-9 |
| 76 | Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. 2021;22:166 doi: 10.1016/j.omto.2021.08.005 |
| 77 | Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy. 2022;345:586 doi: 10.1016/j.jconrel.2022.03.045 |
| 78 | New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. 2022;24:651 doi: 10.1007/s11912-022-01218-y |
| 79 | The Intriguing History of Cancer Immunotherapy. 2019;10: doi: 10.3389/fimmu.2019.02965 |
| 80 | Immunotherapies for hepatocellular carcinoma. 2022;11:571 doi: 10.1002/cam4.4468 |
| 81 | Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. 2020;16:62 doi: 10.2174/1573394715666190913184853 |
| 82 | Nanotherapeutics in Cancer Vaccination and Challenges. 2022;295 doi: 10.1016/B978-0-12-823686-4.00019-7 |
| 83 | Advanced Fermentation and Cell Technology. 2021;579 doi: 10.1002/9781119042792.part3 |
| 84 | Exploiting Cancer’s Tactics to Make Cancer a Manageable Chronic Disease. 2020;12:1649 doi: 10.3390/cancers12061649 |
| 85 | Immunotherapy. 2020;1244:255 doi: 10.1007/978-3-030-41008-7_13 |
| 86 | Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. 2020;6:29 doi: 10.1007/s40883-019-00113-6 |
| 87 | Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. 2020;12:432 doi: 10.3390/cancers12020432 |
| 88 | Drug Repurposing for Triple-Negative Breast Cancer. 2020;10:200 doi: 10.3390/jpm10040200 |
| 89 | The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. 2022;Publish Ahead of Print: doi: 10.1097/CAD.0000000000001463 |
| 90 | Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. 2022;23:127 doi: 10.1080/15384047.2022.2033057 |
| 91 | Immune System Efficiency in Cancer and the Microbiota Influence. 2021;88:170 doi: 10.1159/000512326 |
| 92 | A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). 2022;48: doi: 10.3892/or.2022.8405 |
| 93 | Understanding immunotherapy and its management. 2021;001 doi: 10.17352/2455-8591.000030 |
| 94 | Immunotherapy: an alternative promising therapeutic approach against cancers. 2022;49:9903 doi: 10.1007/s11033-022-07525-8 |
| 95 | ; ; ; doi: |
| 96 | Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT-CRP Induces Selective ROS-Dependent Apoptosis in T-Acute Lymphoblastic Leukemia Cell Lines. 2020;2020:1 doi: 10.1155/2020/1598503 |
| 97 | Recent Progress in the Synergistic Combination of Nanoparticle‐Mediated Hyperthermia and Immunotherapy for Treatment of Cancer. 2021;10:2001415 doi: 10.1002/adhm.202001415 |
| 98 | A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model. 2021;13:407 doi: 10.3390/cancers13030407 |
| 99 | Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma. 2021;12: doi: 10.3389/fgene.2021.744304 |
| 100 | Cell membrane coated-nanoparticles for cancer immunotherapy. 2022;12:3233 doi: 10.1016/j.apsb.2022.02.023 |
| 101 | Emerging Trends in Immunotherapy for Cancer. 2022;10:60 doi: 10.3390/diseases10030060 |
| 102 | Editorial. 2020;43:5 doi: 10.1159/000510546 |
| 103 | Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy. 2022;4: doi: 10.3389/fnano.2022.911063 |
| 104 | The emergence of drug resistance to targeted cancer therapies: Clinical evidence. 2019;47:100646 doi: 10.1016/j.drup.2019.100646 |
| 105 | Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6 |
| 106 | Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated—A Systematic Review. 2022;2022:1 doi: 10.1155/2022/8549532 |
| 107 | Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139 |
| 108 | Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors. 2022; doi: 10.7759/cureus.32710 |
| 109 | Recent advancements in immunotherapy of melanoma using nanotechnology-based strategies. 2023;159:114243 doi: 10.1016/j.biopha.2023.114243 |
| 110 | Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433 |
| 111 | Pembrolizumab: The Nut Cracker. 2020;41:393 doi: 10.4103/ijmpo.ijmpo_37_20 |
| 112 | Biomaterial Based Approaches to Study the Tumour Microenvironment. 2022;342 doi: 10.1039/9781839166013-00342 |
| 113 | Handbook of Cancer and Immunology. 2022;1 doi: 10.1007/978-3-030-80962-1_183-1 |
| 114 | Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments. 2020;49:726 doi: 10.1080/08820139.2020.1748047 |
| 115 | Editorial. 2019;12:3 doi: 10.1111/ors.12402 |
| 116 | Ecology of Fear: Spines, Armor and Noxious Chemicals Deter Predators in Cancer and in Nature. 2021;9: doi: 10.3389/fevo.2021.682504 |
| 117 | The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets. 2022;18:117 doi: 10.2217/fon-2021-1110 |
| 118 | Active immunotherapy of cancer: An overview of therapeutic vaccines. 2019;69:490 doi: 10.5937/arhfarm1906490F |
| 119 | Combined strategies for tumor immunotherapy with nanoparticles. 2019;21:1441 doi: 10.1007/s12094-019-02081-3 |
| 120 | Modeling immune cell behavior across scales in cancer. 2020;12: doi: 10.1002/wsbm.1484 |
| 121 | Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. 2019;11:248 doi: 10.1007/s12609-019-00332-4 |
| 122 | The exploitation of enzyme-based cancer immunotherapy. 2022;36:98 doi: 10.1007/s13577-022-00821-2 |
| 123 | Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396 |
| 124 | Trends in Biomathematics: Stability and Oscillations in Environmental, Social, and Biological Models. 2022;225 doi: 10.1007/978-3-031-12515-7_12 |
| 125 | Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. 2021;22:1301 doi: 10.1007/s10198-021-01337-6 |
| 126 | On the very idea of pursuitworthiness. 2022;91:103 doi: 10.1016/j.shpsa.2021.11.016 |
| 127 | Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. 2020;37:354 doi: 10.1016/j.ccell.2020.02.001 |
| 128 | Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. 2020;34:749 doi: 10.1007/s40259-020-00450-x |
| 129 | Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management. 2020;52:402 doi: 10.4103/ijp.IJP_475_18 |
| 130 | A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. 2019;18:1081 doi: 10.1158/1535-7163.MCT-18-0737 |
| 131 | Immunotherapy and other systemic therapies for cutaneous SCC. 2019;99:104459 doi: 10.1016/j.oraloncology.2019.104459 |
| 132 | Fatty Acid Metabolism and Cancer Immunotherapy. 2022;24:659 doi: 10.1007/s11912-022-01223-1 |
| 133 | Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy. 2022;22: doi: 10.4110/in.2022.22.e3 |
| 134 | On the development of a neoantigen vaccine for the prevention of Lynch Syndrome. 2022;151:107 doi: 10.1002/ijc.33971 |
| 135 | O-acetylated Gangliosides as Targets for Cancer Immunotherapy. 2020;9:741 doi: 10.3390/cells9030741 |
| 136 | Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. 2020;20: doi: 10.1186/s12874-020-00997-x |
| 137 | The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. 2022;29: doi: 10.1186/s12929-022-00796-0 |
| 138 | The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. 2020;10:666 doi: 10.3390/biom10050666 |
| 139 | RNA methylation and cellular response to oxidative stress-promoting anticancer agents. 2023;1 doi: 10.1080/15384101.2023.2165632 |
| 140 | Immunity Management Post Cancer Therapy. 2022;24 doi: 10.52711/2231-5691.2022.00005 |
| 141 | Novel therapeutic strategies for spinal osteosarcomas. 2020;64:83 doi: 10.1016/j.semcancer.2019.05.018 |
| 142 | Spontaneous regression of adenocarcinoma of submandibular gland. 2021;87:486 doi: 10.1016/j.bjorl.2020.10.014 |
| 143 | Recent progress in cancer immunotherapy: Overview of current status and challenges. 2023;241:154241 doi: 10.1016/j.prp.2022.154241 |
| 144 | The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. 2022;14:397 doi: 10.3390/pharmaceutics14020397 |
| 145 | Tumor-associated macrophages: Shifting bad prognosis to improved efficacy in cancer therapies?. 2021;015 doi: 10.17352/2455-8591.000032 |
| 146 | Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer: a meta-analysis. 2020;9:1285 doi: 10.2217/cer-2020-0040 |
| 147 | Recent Advances in the Use of Plant Virus-Like Particles as Vaccines. 2020;12:270 doi: 10.3390/v12030270 |
| 148 | Recent developments in antibody derivatives against colorectal cancer; A review. 2021;265:118791 doi: 10.1016/j.lfs.2020.118791 |
| 149 | An Overview on Immunogenic Cell Death in Cancer Biology and Therapy. 2022;14:1564 doi: 10.3390/pharmaceutics14081564 |
| 150 | Cancer: The Enemy from Within. 2020;223 doi: 10.1007/978-3-030-40651-6_9 |
| 151 | Burger's Medicinal Chemistry and Drug Discovery. 2021;1 doi: 10.1002/0471266949.bmc157.pub2 |
| 152 | Learning-accelerated discovery of immune-tumour interactions. 2019;4:747 doi: 10.1039/C9ME00036D |
| 153 | Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. 2021;43: doi: 10.1111/pim.12825 |
| 154 | Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. 2020;112:562 doi: 10.1093/jnci/djaa021 |
| 155 | Immunotherapy. 2021;1342:357 doi: 10.1007/978-3-030-79308-1_14 |
| 156 | Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma. 2022;12:2820 doi: 10.1158/2159-8290.CD-22-0196 |
| 157 | Resistance to Targeted Therapies in Lymphomas. 2019;21:155 doi: 10.1007/978-3-030-24424-8_7 |
| 158 | Cardiovascular toxicity and therapeutic modalities targeting cardio-oncology. 2022;39 doi: 10.1016/B978-0-323-90461-2.00001-8 |
| 159 | A guide to cancer immunotherapy: from T cell basic science to clinical practice. 2020;20:651 doi: 10.1038/s41577-020-0306-5 |
| 160 | Nanoformulation Strategies for Cancer Treatment. 2021;207 doi: 10.1016/B978-0-12-821095-6.00003-3 |
| 161 | Humanized Germ-Free Mice for Investigating the Intervention Effect of Commensal Microbiome on Cancer Immunotherapy. 2022;37:1291 doi: 10.1089/ars.2022.0039 |
| 162 | Molecular Stacking Composite Nanoparticles of Gossypolone and Thermodynamic Agent for Elimination of Large Tumor in Mice via Electrothermal‐Thermodynamic‐Chemo Trimodal Combination Therapy. 2022;32:2201666 doi: 10.1002/adfm.202201666 |
| 163 | Current trends in cancer immunotherapy: a literature-mining analysis. 2020;69:2425 doi: 10.1007/s00262-020-02630-8 |
| 164 | Translational Biotechnology. 2021;233 doi: 10.1016/B978-0-12-821972-0.00014-9 |
| 165 | Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. 2019;19:2158 doi: 10.2174/1568026619666190904163524 |
| 166 | Redrawing therapeutic boundaries: microbiota and cancer. 2022;8:87 doi: 10.1016/j.trecan.2021.10.008 |
| 167 | Microsatellite Instability in Russian Patients with Colorectal Cancer. 2022;23:7062 doi: 10.3390/ijms23137062 |
| 168 | miRNAs as novel immunoregulators in cancer. 2022;124:3 doi: 10.1016/j.semcdb.2021.04.013 |
| 169 | Nanoparticles: Properties and Applications in Cancer Immunotherapy. 2019;25:1962 doi: 10.2174/1381612825666190708214240 |
| 170 | Precision Medicine in Oncology. 2020;133 doi: 10.1002/9781119432487.ch5 |
Journal of Cancer Metastasis and Treatment
